U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000049: Pediatric Inflammatory Crohn’s MRE Index (PICMI)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000049: Pediatric Inflammatory Crohn’s MRE Index (PICMI)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Immunology and Inflammation (OII)
Division of Gastroenterology (DG)


DDT COA Number
DDT COA #000049

Instrument Name
Pediatric Inflammatory Crohn’s MRE Index (PICMI)

Disease/Condition
Crohn’s Disease

Concept of Interest
Disease Activity

Context of Use
Children (5-17 years) with CD

COA Type
ClinRO

Qualification Stage
Letter of Intent-Accepted 

Requestor(s)
Dan Turner
Anne Griffiths

Contact(s)
Dan Turner
Anne Griffiths

Date Accepted into CDER’s COA Qualification Program
November 16, 2012

Submission and Regulatory Correspondence History

Qualification Submission

Date

FDA Submission Decision & Recommendations

Date

--

--

Transition Letter to 507 Process

9/9/19

Back to Top